



# NETWORK *Notification*

**Notice Date:** April 12, 2021  
**To:** Indiana Medicaid Providers  
**From:** CareSource  
**Subject:** Amondys 45 Rx Update

---

## Summary

CareSource Indiana would like to share an update for a new medication intended for the treatment of muscular dystrophy. [The U.S. Food and Drug Administration \(USDA\) has approved](#) the Amondys 45 injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping ([Exons](#) are pieces of DNA that provide information for making proteins in a person's genome).

## Impact

While this drug is covered for Indiana Medicaid members enrolled in Healthy Indiana Plan (HIP) or Hoosier Healthwise (HHW), reimbursement will be carved out of managed care. Amondys 45 will be covered by the fee-for-service pharmacy benefit. Reimbursement under the medical benefit will not be available until a specific HCPCS code becomes available.

Note about reimbursement: On Feb. 9, 2021 the Indiana Health Coverage Programs (IHCP) released updated information on physician-administered drugs carved out of managed care and reimbursable outside the inpatient-related group. The detailed information can be found [here](#).

These medications should not be billed to the managed care organizations.

## Questions?

For questions, please contact Provider Services at **1-800-607-2831** (Monday through Friday, 8 a.m. to 6 p.m. EST).

IN-MED-P-475740 Issued Date: 4/6/2021

OMPP Approved: 4/6/2021